Hon Hai Precision Industry Co. LT.../ US4380908057 /
6/19/2024 10:31:27 AM | Chg. +0.14 | Volume | Bid1:00:05 PM | Ask1:00:29 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
12.48USD | +1.13% | 12,726 Turnover: 160,802.58 |
12.50Bid Size: 991 | 12.54Ask Size: 648 | 227.12 bill.USD | - | - |
GlobeNewswire
1:00 PM
PyroGenesis Receives Second Order for Titanium Metal Powder from Spanish Aerospace Client
GlobeNewswire
10:00 AM
Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Co...
GlobeNewswire
6/18
Mercury Appoints Senior Vice President of Operations, Completes Second Phase of Organizational Restr...
GlobeNewswire
6/18
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
GlobeNewswire
6/18
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwoo...
GlobeNewswire
6/18
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global...
GlobeNewswire
6/18
After 11-Year Journey, HordRT Reshapes Product Development Cycles through Breakthrough Rapid Tooling...
GlobeNewswire
6/18
Primarius to Feature Fast, Accurate Modeling, Characterization, Simulation Solutions at 61st Design ...
GlobeNewswire
6/18
Truveta announces support for regulatory submissions to the FDA and global regulatory authorities
GlobeNewswire
6/18
ALVERNO LABORATORIES LAUNCHES INTO THE ERA OF AI-POWERED PATHOLOGY WITH IBEX MEDICAL ANALYTICS
GlobeNewswire
6/18
Reborn Coffee Launches on Amazon, Expanding OMNI-Channel Strategy for E-Commerce Growth
GlobeNewswire
6/18
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
GlobeNewswire
6/18
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients...
GlobeNewswire
6/18
authID and Syntrove Announce OEM Partnership for authID’s Secure Biometric Identity Services
GlobeNewswire
6/18
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...
GlobeNewswire
6/18
Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembr...